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Introduction: Dyslipidemia is an important risk factor for cardiovascular disease due to the 
significant influence of cholesterol on atherosclerosis. Several genetic variants in genes related 
with triglyceride (TG) metabolism has been described, including LPL, apolipoprotein A5 and 
apolipoprotein E (Apo E) are associated with dyslipidemia by involvement to lipid metabolism. The 
combined analysis of these polymorphisms could produce clinically meaningful complementary 
information. Changes in TG levels are now considered an independent cardiovascular risk 
factor; hence, the study of combined variants in genes involved in TG metabolism may help 
explain part of the risk for CVD. The most informative polymorphisms within the Apo E gene are 
the Arg158Cys (rs7412) and Cys112Arg (rs429358) which define Apo E gene alleles, epsilon2, 
3 and 4 (£2, £3 and £4). 
Methods: Healthy volunteers aged 50-75 years randomly selected from registers of the 
polyclinics in Astana. Biochemical analysis blood was performed from serum for the total 
cholesterol (TC), TG, and level of HDLs and LDLs on COBAS Integra 400. Genomic DNA was 
extracted from peripheral blood using the Promega Wizard® Genomic DNA Purification Kit. 
The SNP genotyping was performed by Real-Time PCR using TaqMan assay on 7900HT Fast 
System (Applied Biosystems, USA). 
Results: The APOE genotypes were clustered into 3 groups: £2/E2+£2/£3, еЗ /еЗ , еЗ/е4+ £4/ 
E4 due to the small number of participants with E2/E2 (n=2), and E4/E4 (n=12) genotypes (minor 
allele frequency, MAF<5%). Analysis was performed by ANOVA for the potential effect of Apo 
E variants on individual cardiometabolic risk factors. Apo E gene variants showed statistically 
significant association with TC level in analysis stratified by ethnicity, age and sex (p=0.002). 
In addition, sex and BMI stratified analysis showed significant association with LDL levels 
(p<0.001) 
Conclusions: Allelic polymorphism of Apo E gene is good genetic prognostic marker of lipid 
metabolism and related diseases. Also it has effect on response to statins, which are widely used 
in lipid lowering therapies, on personalized level. Considering information mentioned above 
genetic screening for Apo E genotype should to be performed prior statin therapy appointment. 
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